



EMLc

ATC codes: [J06BB02](#)

|                          |  |
|--------------------------|--|
| Indication               | Tetanus <a href="#">ICD11 code: 1C13</a>   |
| Medicine type            | Biological agent   |
| List type                | Core (EML) (EMLc)  |
| Additional notes         | All human plasma-derived medicines should comply with the WHO requirements   |
| Formulations             | Parenteral > General injections > IM: 500 IU in vial   |
| EML status history       | First added in 1984 ( <a href="#">TRS 722</a> )<br>Changed in 1989 ( <a href="#">TRS 796</a> )<br>Changed in 1991 ( <a href="#">TRS 825</a> )<br>Changed in 2003 ( <a href="#">TRS 920</a> )<br>Changed in 2007 ( <a href="#">TRS 950</a> )<br>Changed in 2015 ( <a href="#">TRS 994</a> ) |
| Sex                      | All  |
| Age                      | Also recommended for children  |
| Therapeutic alternatives | The recommendation is for this specific medicine   |
| Patent information       | Read more <a href="#">about patents.</a>   |

Tags

Biological

Wikipedia

[Anti-tetanus immunoglobulin](#)

DrugBank

[Anti-tetanus immunoglobulin \(Tetanus Immune Globulin\)](#)

## Summary of evidence and Expert Committee recommendations

The Expert Committee recommended that immunoglobulins of human origin currently listed in Section 19.2 Sera and immunoglobulins, should be transferred to Section 11.2.1 Human immunoglobulins.

